DUBLIN--(BUSINESS WIRE)--The "Rectal
Cancer - Pipeline Review, H2 2018" drug pipelines has been
added to ResearchAndMarkets.com's offering.
Rectal Cancer - Pipeline Review, H2 2018, provides
comprehensive information on the therapeutics under development for
Rectal Cancer (Oncology), complete with analysis by stage of
development, drug target, mechanism of action (MoA), route of
administration (RoA) and molecule type.
The guide covers the descriptive pharmacological action of the
therapeutics, its complete research and development history and latest
news and press releases.
The Rectal Cancer (Oncology) pipeline guide also reviews of key players
involved in therapeutic development for Rectal Cancer and features
dormant and discontinued projects.
The guide covers therapeutics under Development by Companies
/Universities /Institutes, the molecules developed by Companies in
Filing rejected/Withdrawn, Phase II, Phase I, IND/CTA Filed, Preclinical
and Discovery stages are 1, 6, 2, 1, 1 and 1 respectively.
Rectal Cancer (Oncology) pipeline guide helps in identifying and
tracking emerging players in the market and their portfolios, enhances
decision making capabilities and helps to create effective counter
strategies to gain competitive advantage.
Eisai Co. Ltd.
Eli Lilly and Co.
NewLink Genetics Corp.
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/xrdzmq/rectal_cancer?w=4